<DOC>
	<DOCNO>NCT00023374</DOCNO>
	<brief_summary>This study prospective , open-label , nonrandomized trial use largely-intermittent , six-month tuberculosis treatment regimen among patient receive isoniazid due presence initial isoniazid resistance intolerance . Subjects enrol resistance intolerance isoniazid document , treat total six month ( nine month baseline chest x-ray show cavitation 2-month sputum culture positive ) twice weekly thrice weekly rifampin , ethambutol , pyrazinamide .</brief_summary>
	<brief_title>TBTC Study 24 : Intermittent Treatment TB With Isoniazid Resistance Intolerance</brief_title>
	<detailed_description>Primary Objective : To evaluate efficacy directly-observed , largely-intermittent , six-month regimen rifampin , pyrazinamide , ethambutol among patient culture confirm isoniazid-resistant M. tuberculosis . Secondary Objectives : To describe rate , severity time toxicity drug intolerance associate treatment regimen . To describe utility regimen among patient unable continue standard 4-drug regimen due development intolerance isoniazid</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>Inclusion criterion : 1 . Cultureconfirmed pulmonary extrapulmonary tuberculosis due strain M tuberculosis sensitive rifampin , ethambutol pyrazinamide base upon specimen ( sputum pulmonary extrapulmonary disease site specimen ) collect 8 week 2 week start initial therapy . Susceptibility test result document susceptibility rifampin ethambutol must available time enrollment . Susceptibility result pyrazinamide may pending enrollment long pyrazinamide resistance know present base prior testing . If pyrazinamide resistance detect confirm ( see Study Definitions ) patient withdrawn study therapy , treatment continue recommended treating physician , followup continue per protocol . 2 . Decision discontinue use isoniazid one follow condition within first 70 day therapy : Isoniazid resistant strain ( growth 0.2 mcg/ml 0.1 mcg/ml isoniazid solid liquid medium , respectively ) The discontinuation isoniazid due intolerance ( judge principal investigator see Study Definitions ) 3 . For patient enrolled start therapy , documentation adequate initial regimen recommend CDC/ATS Treatment Guidelines ( Appendix 1 ) require . There two mean requirement meet : The standard 4drug regimen isoniazid , rifampin , pyrazinamide , either ethambutol streptomycin . The regimen isoniazid excluded dos patient know isoniazid intolerance tuberculosis due isoniazidresistant strain ( i.e. , 3drug regimen rifampin , pyrazinamide either ethambutol streptomycin ) 4 . A minimum duration daily treatment define one two method : 14 daily dos within 17 day ( least 10 14 dos directly observe ) 14 directly observe dos within 23 day Following minimum daily phase therapy , adequate preenrollment treatment define directly administer therapy give daily , twice weekly , thrice weekly use CDC/ATS guideline . Documenting preenrollment therapy accomplish hospital medical record and/or clinic entry DOT . 5 . Age : 18 year old 6 . Documentation negative test human immunodeficiency virus ( HIV ) infection . Documentation mean write copy HIV laboratory test result . A negative HIV test result within 6 month prior enrollment acceptable . 7 . Documentation study baseline laboratory parameter . Baseline laboratory parameter obtain 2 week prior enrollment must within follow limit : 1. . Amino aspartate transferase ( AST ) activity le 3 time upper limit normal ; 2. . Total bilirubin level le 2.5 time upper limit normal ; 3. . Creatinine level le 2 time upper limit normal ; 4. . Hemoglobin level least 7.0 g/dL ; 5. . Platelet count least 50,000 mm3 8 . Karnofsky score least 60 . See Appendix 6 Karnofsky scoring system . 9 . A negative pregnancy test within past 14 day woman childbearing potential , willingness practice adequate ( preferably barrier ) method birth control . In addition , woman childbearing potential offer information concern source contraceptive counseling service . 10 . Informed consent sign patient investigator document willingness use 3drug , intermittent regimen require , accordance state law local IRB requirement . Patients unable provide inform consent due inability comprehend English may enrol provide informed consent either two mean : use translator provide verbal translation IRBapproved English version consent form ; translator sign English form attest translation patient sign IRBapproved translation short form use translate consent document , approve IRB , patient 's native language . Exclusion criteria 1 . Patients know treatmentlimiting reaction rifamycins , pyrazinamide , ethambutol . 2 . Diagnosis silicotuberculosis tuberculosis central nervous system 3 . Patients , initial therapy CDC/ATS recommend therapy isoniazid , rifampin pyrazinamide plus either ethambutol streptomycin , receive great 21 day treatment additional drug know antituberculosis activity see Concomitant Medications During Study Phase Therapy . 4 . Patients isoniazid intolerance isoniazidresistant tuberculosis preenrollment therapy miss total two week directly observe therapy dos due noncompliance . 5 . Patients enrol due isoniazid intolerance preenrollment therapy miss total 4 week directly observe therapy dos management drug intolerance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>TB</keyword>
	<keyword>isoniazid resistance</keyword>
	<keyword>isoniazid intolerance</keyword>
	<keyword>treatment</keyword>
	<keyword>efficacy</keyword>
	<keyword>toxicity</keyword>
</DOC>